loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account
IPOLogoImag

BLUE JET HEALTHCARE LTD IPO

IPO Details

-
-
43 Shares
₹ 14,878
₹ 329 – 346
₹ Up to 840.27 Cr

Issue timeline

  • -
  • 01-Nov-2023
  • 01-Nov-2023
  • 03-Nov-2023
  • 06-Nov-2023

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

- A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products targeted toward innovator pharmaceutical companies and multi-national generic pharmaceutical companies.(Source: CRISIL Report)

-In the past three Financial Years, they invoiced a total of more than 350 customers in 35 countries

-Their operations are organized in three product categories: (i) contrast media intermediates, (ii) high intensity sweeteners, and (iii) pharma intermediates and active pharmaceutical ingredients (“APIs”)

Strengths & Risks

Strengths (3)

Large manufacturer of contrast media intermediates in India
With more than two decades of experience in manufacturing contrast media intermediates, they are a large manufacturer of contrast media intermediates in India.(Source: Company DRHP)

Risks (2)

Inability to accurately forecast demand for products may have an adverse effect on business
Their business depends on estimate of the long-term demand for their products from customers. Although their long-term relationships with customers provide them with visibility of their volume offtake in the near future and they may base production capacity on medium- to long-term supply contracts with them as well as their forecast of procurement volume, they cannot assure such estimates or forecast would be accurate. Inability to accurately forecast demand for products and manage inventories may have an adverse effect on business (Source: Company DRHP)

  • Large manufacturer of contrast media intermediates in India
    With more than two decades of experience in manufacturing contrast media intermediates, they are a large manufacturer of contrast media intermediates in India.(Source: Company DRHP)

  • Presence in niche categories with high barriers to entry
    They strategically focus on complex chemistry categories in both the contrast media intermediate and high-intensity sweetener categories, specifically on products required by customers, and products selected by internal product portfolio team. (Source: Company DRHP)

  • Manufacturing facilities with regulatory accreditations
    They currently operate three manufacturing facilities, which are located in Shahad (Unit I), Ambernath (Unit II) and Mahad (Unit III) in the state of Maharashtra, India which have received accreditation from various regulatory agencies. In particular, Unit II facility has been subject to US-FDA inspections in the Financial Year 2018, following which, it received the US-FDA establishment inspection report in November 2019.(Source: Company DRHP)

  • Inability to accurately forecast demand for products may have an adverse effect on business
    Their business depends on estimate of the long-term demand for their products from customers. Although their long-term relationships with customers provide them with visibility of their volume offtake in the near future and they may base production capacity on medium- to long-term supply contracts with them as well as their forecast of procurement volume, they cannot assure such estimates or forecast would be accurate. Inability to accurately forecast demand for products and manage inventories may have an adverse effect on business (Source: Company DRHP)

  • They face foreign exchange risks that could adversely affect results of operations and cash flows
    A significant portion of their total revenue from operations is denominated in currencies other than Indian Rupees. They monitor their exposure to foreign currencies and selectively enter into hedging transactions in an attempt to reduce the risks of currency fluctuations. In addition, the policies of the RBI may also change from time to time, which may limit their ability to effectively hedge foreign currency exposures and may have an adverse effect on results of operations and cash flows(Source: Company DRHP)

Financials

Net Worth
Total Income
Profit after Tax
Earning Per Share

Industry Overview

Increased propensity to outsource manufacturing of intermediates and APIs : Both – innovator companies and generics companies have been increasingly outsourcing manufacturing of intermediates to contract development and manufacturing organizations (CDMOs)


High-intensity sweeteners market is estimated to grow :  High-intensity sweeteners market is estimated to grow at a CAGR in the range of 4% to 5% over the next 5 years, on account of growing incidence of diabetes and obesity, Shifting consumer preference and Rising urbanization and changing lifestyle resulting in higher consumption of ready-to-eat / processed foods (Source: Company DRHP)

vishal-mega-mart IPO

Blue Jet Healthcare Ltd IPO

₹ 14,878
43 Shares

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

Download
ICICI Direct app

market app

*The financials mentioned above are sourced from DRHP/ RHP documents.

✕
Application status